Patents by Inventor Om P. Goel

Om P. Goel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200237729
    Abstract: The present invention concerns the synthesis and use of formulations of 5-substituted 2, 4-thiazolidinediones, pseudothiohydantoins, and propseudothiohydantoins and 2, 4-thiazolidinediones metforminate salts for topical and systemic treatments of infections caused by Herpes simplex viruses and Varicella zoster viruses.
    Type: Application
    Filed: April 4, 2020
    Publication date: July 30, 2020
    Applicant: Jiva Pharma, Inc.
    Inventor: Om P Goel
  • Patent number: 10646477
    Abstract: The present invention concerns the synthesis and use of formulations of 5-substituted 2, 4-thiazolidinediones, pseudothiohydantoins, and propseudothiohydantoins and 2, 4-thiazolidinediones metforminate salts for topical and systemic treatments of infections caused by herpes simplex viruses and varicella zoster viruses.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: May 12, 2020
    Assignee: Jiva Pharma, Inc.
    Inventor: Om P Goel
  • Patent number: 10125078
    Abstract: The present invention relates to the NSAID derivatives of omega-3 fatty acids as gamma secretase modulators and their use in treating Alzheimer's disease, hypertriglyceridemia, and cardiovascular disease by reducing triglycerides, and for use as anti-inflammatory agents.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: November 13, 2018
    Assignee: Jiva Pharma Inc.
    Inventor: Om P Goel
  • Publication number: 20170327455
    Abstract: The present invention relates to the fibric acid derivatives of omega-3 fatty acids and their use in treating Type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic syndrome, cancer, Alzheimer's disease; and their use for modulating activity of peroxisome proliferator-activated receptors (PPARs).
    Type: Application
    Filed: July 30, 2017
    Publication date: November 16, 2017
    Applicant: Jiva Pharma, Inc.
    Inventor: Om P. Goel
  • Patent number: 9815777
    Abstract: Metformin salts of 2,4-thiazolidinediones are described for the treatment of diabetes mellitus Type2, gestational diabetes, polycystic ovary syndrome, non-alcoholic fatty liver disease, coronary artery disease, pancreatic cancer, premature puberty, and other diseases which manifest insulin resistance.
    Type: Grant
    Filed: September 20, 2014
    Date of Patent: November 14, 2017
    Assignee: Jiva Pharma, Inc.
    Inventor: Om P Goel
  • Patent number: 9808497
    Abstract: The present invention describes a formulation comprising a prune and/or plum concentrate, and one or more water-soluble, non-digestible, prebiotic oligosaccharides. Optionally, one or more low calorie sweeteners, an antioxidant, calcium sennosides, or sennosides extract, PEG-3350, licorice, cocoa, coffee, tea flavors; fruit flavorings and spice flavorings, gelatin, agar-agar, carrageenan, pectin or cocoa powder are added. Other ingredients may be present as dietary supplements such as water-soluble vitamins, lipid-soluble vitamins; amino acids, maltodextrin, resveratrol, caffeine, mineral supplements, or natural sleep aids for use as a laxative, A variety of formulations are possible, such as premix, a laxative+energy power drink or power bar, or as a prebiotic supplement in probiotic yogurts, or in the form of gummies, chocolates, candies, and desserts such as red beans Japanese desserts.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: November 7, 2017
    Assignee: Jiva Pharma, Inc.
    Inventor: Om P Goel
  • Patent number: 9688613
    Abstract: The present invention relates to omegabalins, which are GABA derivatives of omega-3 fatty acids, and their use in pharmaceutically-acceptable formulations for treating neuropathic pain, fibromyalgia, epilepsy, anxiety, depression, insomnia, Alzheimer's disease, and other neurological conditions.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: June 27, 2017
    Assignee: Jiva Pharma, Inc.
    Inventor: Om P Goel
  • Patent number: 9540307
    Abstract: The present invention relates to novel statin derivatives of omega-3 fatty acids, and their use in treating hypercholesterolemia, obesity, hypertriglyceridemia, cardiovascular diseases, and metabolic diseases, and Alzheimer's disease.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: January 10, 2017
    Assignee: JIVA PHARMA, INC.
    Inventor: Om P Goel
  • Publication number: 20160376223
    Abstract: The present invention relates to omegabalins, which are GABA derivatives of omega-3 fatty acids, and their use in pharmaceutically-acceptable formulations for treating neuropathic pain, fibromyalgia, epilepsy, anxiety, depression, insomnia, Alzheimer's disease, and other neurological conditions.
    Type: Application
    Filed: June 22, 2016
    Publication date: December 29, 2016
    Applicant: Jiva Pharma, Inc.
    Inventor: Om P. Goel
  • Publication number: 20160229796
    Abstract: Metformin salts of 2,4-thiazolidinediones are described for the treatment of diabetes mellitus Type2, gestational diabetes, polycystic ovary syndrome, non-alcoholic fatty liver disease, coronary artery disease, pancreatic cancer, premature puberty, and other diseases which manifest insulin resistance.
    Type: Application
    Filed: September 20, 2014
    Publication date: August 11, 2016
    Applicant: Jiva Pharma, Inc.
    Inventor: Om P Goel
  • Patent number: 9364465
    Abstract: The present invention relates to thiazolidinedione derivatives of omega-3 fatty acids as insulin sensitizers, and their use in treating Type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic diseases, inflammation, renal anemia, and/or Alzheimer's disease: and for modulating activity of peroxisome proliferator-activated receptors (PPARs).
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: June 14, 2016
    Assignee: Jiva Pharma, Inc
    Inventor: Om P Goel
  • Publication number: 20160051521
    Abstract: The present invention relates to thiazolidinedione derivatives of omega-3 fatty acids as insulin sensitizers, and their use in treating Type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic diseases, inflammation, renal anemia, and/or Alzheimer's disease: and for modulating activity of peroxisome proliferator-activated receptors (PPARs).
    Type: Application
    Filed: March 28, 2014
    Publication date: February 25, 2016
    Applicant: JIVA PHARMA, INC.
    Inventor: Om P Goel
  • Publication number: 20150374660
    Abstract: The present invention provides ascorbate esters of omega-3 fatty acids as their pharmaceutically-acceptable salts and pharmaceutically-acceptable formulations for use as dietary supplements with enhanced antioxidant properties, in improving the effectiveness of other drugs and in treatment of hypertriglyceridemia, hypercholestolemia, diabetes, psychiatric and neurological disorders, attention deficit and hyperactivity disorder, and as cosmeceuticals.
    Type: Application
    Filed: February 25, 2014
    Publication date: December 31, 2015
    Applicant: JIVA PHARMA, INC.
    Inventor: Om P Goel
  • Publication number: 20150344402
    Abstract: The present invention relates to the fibric acid derivatives of omega-3 fatty acids and their use in treating Type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic syndrome, cancer, Alzheimer's disease; and their use for modulating activity of peroxisome proliferator-activated receptors (PPARs).
    Type: Application
    Filed: May 26, 2015
    Publication date: December 3, 2015
    Applicant: JIVA PHARMA, INC.
    Inventor: Om P. Goel
  • Publication number: 20150322032
    Abstract: The present invention relates to novel statin derivatives of omega-3 fatty acids, and their use in treating hypercholesterolemia, obesity, hypertriglyceridemia, cardiovascular diseases, and metabolic diseases, and Alzheimer's disease.
    Type: Application
    Filed: May 7, 2015
    Publication date: November 12, 2015
    Applicant: Jiva Pharma, Inc.
    Inventor: Om P Goel
  • Publication number: 20140308374
    Abstract: The present invention describes a formulation comprising a prune and/or plum concentrate, and one or more water-soluble, non-digestible, prebiotic oligosaccharides. Optionally, one or more low calorie sweeteners, an antioxidant, calcium sennosides, or sennosides extract, PEG-3350, licorice, cocoa, coffee, tea flavors; fruit flavorings and spice flavorings, gelatin, agar-agar, carrageenan, pectin or cocoa powder are added. Other ingredients may be present as dietary supplements such as water-soluble vitamins, lipid-soluble vitamins; amino acids, maltodextrin, resveratrol, caffeine, mineral supplements, or natural sleep aids for use as a laxative, A variety of formulations are possible, such as premix, a laxative+energy power drink or power bar, or as a prebiotic supplement in probiotic yogurts, or in the form of gummies, chocolates, candies, and desserts such as red beans Japanese desserts.
    Type: Application
    Filed: November 2, 2012
    Publication date: October 16, 2014
    Applicant: Jiva Pharma, Inc.
    Inventor: Om P Goel
  • Patent number: 8247398
    Abstract: The present invention relates to the use of zinc complexes of natural amino acids, especially L-arginine, L-lysine, L-ornithine, and other natural amino acids, in a molar ratio of about 1:2 (metal:amino acid), and formulations thereof. These pharmaceutical compositions offer better tolerated and faster acting regimens than common zinc salts (i.e., acetate, sulfate, etc.) for long term maintenance therapy of diseases caused by abnormal elevated copper levels, such as in Wilson's disease, inflammatory and fibrotic diseases and Alzheimer's disease.
    Type: Grant
    Filed: February 17, 2007
    Date of Patent: August 21, 2012
    Assignee: SSV Therapeutics, Inc.
    Inventor: Om P. Goel
  • Patent number: 8049038
    Abstract: This invention concerns compounds of adamantanamines and neramexane, including their pharmaceutically-acceptable salts, diesterioisomers, and formulations for treating Alzheimer's related dementias, depression, AIDS related dementias, as antivirals, inflammatory diseases such as rheumatoid arthritis, and cerebral ischemia, hyperlipidemia, and diabetes.
    Type: Grant
    Filed: May 7, 2011
    Date of Patent: November 1, 2011
    Assignee: SSV Therapeutics, Inc.
    Inventor: Om P. Goel
  • Publication number: 20110212166
    Abstract: This invention concerns compounds of adamantanamines and neramexane, including their pharmaceutically-acceptable salts, diesterioisomers, and formulations for treating Alzheimer's related dementias, depression, AIDS related dementias, as antivirals, inflammatory diseases such as rheumatoid arthritis, and cerebral ischemia, hyperlipidemia, and diabetes.
    Type: Application
    Filed: May 7, 2011
    Publication date: September 1, 2011
    Applicant: SSV Therapeutics, Inc.
    Inventor: Om P. Goel
  • Patent number: 7977511
    Abstract: This invention concerns compounds of adamantanamines and neramexane, including their pharmaceutically-acceptable salts, diesterioisomers, and formulations for treating Alzheimer's related dementias, depression, AIDS related dementias, as antivirals, inflammatory diseases such as rheumatoid arthritis, and cerebral ischemia, hyperlipidemia, and diabetes.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: July 12, 2011
    Assignee: SSV Therapeutics, Inc.
    Inventor: Om P. Goel